Wedbush Reaffirms “Outperform” Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a research note issued on Friday, MarketBeat Ratings reports. They presently have a $181.00 price objective on the biotechnology company’s stock. Wedbush’s price objective would suggest a potential upside of 43.07% from the company’s previous close.

A number of other equities analysts have also weighed in on the stock. Citigroup lifted their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Jefferies Financial Group increased their price objective on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th. TD Cowen raised their target price on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Oppenheimer restated an “outperform” rating and set a $190.00 target price (up from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, September 17th. Finally, The Goldman Sachs Group lifted their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $191.77.

Ascendis Pharma A/S Trading Up 1.8 %

Shares of Ascendis Pharma A/S stock opened at $126.51 on Friday. Ascendis Pharma A/S has a 12-month low of $90.13 and a 12-month high of $161.00. The firm has a market capitalization of $7.67 billion, a price-to-earnings ratio of -13.59 and a beta of 0.66. The firm’s 50 day simple moving average is $132.30 and its two-hundred day simple moving average is $132.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. On average, sell-side analysts predict that Ascendis Pharma A/S will post -7.35 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Institutional investors and hedge funds have recently made changes to their positions in the business. Signaturefd LLC increased its holdings in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 80 shares in the last quarter. Profund Advisors LLC lifted its stake in Ascendis Pharma A/S by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock worth $398,000 after purchasing an additional 85 shares in the last quarter. Rhumbline Advisers lifted its holdings in Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Ascendis Pharma A/S by 0.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock worth $11,717,000 after purchasing an additional 228 shares during the period. Finally, Avior Wealth Management LLC increased its position in shares of Ascendis Pharma A/S by 3.0% during the third quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company’s stock worth $1,226,000 after acquiring an additional 240 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.